Kilian O, Dahse R, Alt V, Zardi L, Rosenhahn J, Exner U, Battmann A, Schnettler R, Kosmehl H
Department of Trauma Surgery, University of Giessen, Germany.
Bone. 2004 Dec;35(6):1334-45. doi: 10.1016/j.bone.2004.08.008.
The extracellular matrix component fibronectin (fn) has fundamental functions in cell attachment, differentiation, proliferation, and migration. Isoforms of cellular fibronectin, named EDA+ fibronectin or embryonal EDB+ fibronectin, are generated by alternative splicing of its mRNA precursors. Little is known about the expression of EDA+ and EDB+ fibronectin splice variants in human bone. The aim of this study was to investigate the expression pattern of fibronectin splice variants in bone cell lines and in different human bone tissue samples (mature bone, early stages of fracture healing, hypotrophic nonunion, osteosarcoma). Analysis was done by immunostaining with recombinant and monoclonal antibodies, qualitative RT-PCR and LightCycler-based real-time quantitative RT-PCR assay. In osteoblast and osteosarcoma cell lines, abundant expression of EDA+ and EDB+ fibronectin was found in immunocytochemistry. High transcription levels of both splice variants mRNA were seen in quantitative RT-PCR in osteosarcoma cell lines. In mature bone, EDA+ and EDB+ were not detectable in immunohistochemistry. Transcription of mRNA in both splice variants was absent in these samples. Early stages of fracture healing and osteosarcoma cell samples exhibited extensive staining for EDA+ and EDB+ fibronectin, and high mRNA levels were found. Both osteosarcoma and bone fracture healing tissue expressed high mRNA levels of the fibronectin splice variants independent of benign or malignant behavior. Low level of EDA+ fibronectin mRNA transcription and focal immunohistochemical staining of EDA+ fibronectin was found in hypotrophic nonunions, whereas EDB+ fibronectin was not detected by immunohistochemistry and qualitative or quantitative PCR. EDA+ fibronectin was found in granulation tissue-forming processes in bone independent from bone-forming activity. EDB+ fibronectin was seen only in high-turnover new osteoid-forming processes like early stages of fracture healing and osteosarcoma and was absent in low-turnover processes like mature bone and hypotrophic nonunion. Both EDA+ and EDB+ fibronectin mark active processes in bone without differentiation between malignant or benign activity. In conclusion, EDA+ and EDB+ fibronectin splice variants are strong markers for active fibrogenetic and osteoid-forming processes in human bones.
细胞外基质成分纤连蛋白(Fn)在细胞黏附、分化、增殖和迁移中具有基本功能。细胞纤连蛋白的亚型,即EDA +纤连蛋白或胚胎型EDB +纤连蛋白,是由其mRNA前体的可变剪接产生的。关于EDA +和EDB +纤连蛋白剪接变体在人骨中的表达知之甚少。本研究的目的是调查纤连蛋白剪接变体在骨细胞系和不同人骨组织样本(成熟骨、骨折愈合早期、营养不良性骨不连、骨肉瘤)中的表达模式。通过用重组抗体和单克隆抗体进行免疫染色、定性逆转录聚合酶链反应(RT-PCR)和基于LightCycler的实时定量RT-PCR分析来完成。在成骨细胞和骨肉瘤细胞系中,免疫细胞化学显示EDA +和EDB +纤连蛋白表达丰富。在骨肉瘤细胞系的定量RT-PCR中,两种剪接变体mRNA均可见高转录水平。在成熟骨中,免疫组织化学检测不到EDA +和EDB +。这些样本中两种剪接变体的mRNA转录均缺失。骨折愈合早期和骨肉瘤细胞样本对EDA +和EDB +纤连蛋白呈现广泛染色,且发现mRNA水平较高。骨肉瘤和骨折愈合组织均表达纤连蛋白剪接变体的高mRNA水平,与良性或恶性行为无关。在营养不良性骨不连中发现EDA +纤连蛋白mRNA转录水平低,且EDA +纤连蛋白有局灶性免疫组织化学染色,而免疫组织化学以及定性或定量PCR均未检测到EDB +纤连蛋白。在骨中,EDA +纤连蛋白存在于形成肉芽组织的过程中,与骨形成活性无关。EDB +纤连蛋白仅见于高转换率的新类骨质形成过程,如骨折愈合早期和骨肉瘤,而在低转换率过程如成熟骨和营养不良性骨不连中不存在。EDA +和EDB +纤连蛋白均标记骨中的活跃过程,而不区分恶性或良性活动。总之,EDA +和EDB +纤连蛋白剪接变体是人类骨骼中活跃的纤维生成和类骨质形成过程的强标记物。